PIRAMAL PHARMA LIMITED vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of PIRAMAL PHARMA LIMITED (PPLPHARMA) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads PPLPHARMA vs TORNTPHARM on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth01
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

31.93
P/E ratio
77.50
3.50
P/B ratio
18.67
0.07%
Dividend yield
0.76%
₹6.67
EPS
₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-3.58%
Return on equity
27.40%
3.00%
Return on capital
15.00%
10.00%
EBITDA margin
33.00%
-3.68%
Net margin
15.29%

Growth

TORNTPHARM takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

2.77%
Revenue CAGR (3Y)
13.27%
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹28,319 Cr
Market cap
₹1.68L Cr
₹8,869 Cr
Revenue
₹13,980 Cr
₹-326 Cr
Net profit
₹2,138 Cr
0.70
Debt / equity
1.69
PIRAMAL PHARMA LIMITED
  • ["Stock is trading at 3.56 times its book value", "Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 7.03% over past five years.", "Company has a low return on equity of -0.88% over last 3 years.", "Company might be capitalizing the interest cost"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
PIRAMAL PHARMA LIMITED full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

PPLPHARMA vs TORNTPHARM: Share Price, Valuation & Which to Buy | DocStoX